Oral HRS-7535 Lowered A1c in Trial - Takeaways - MDSpire

Oral HRS-7535 Lowered A1c in Trial

Nonpeptide oral agent requires no fasting administration.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 9 min

Share

  • 1

    Oral HRS-7535 significantly reduced hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled by metformin.

  • 2

    The trial involved 194 patients and demonstrated that HRS-7535 doses of 60 mg and 90 mg provided similar glycemic control.

  • 3

    Patients receiving HRS-7535 achieved greater reductions in fasting plasma glucose and postprandial glucose compared to placebo.

  • 4

    Gastrointestinal adverse events were common but mostly mild or moderate, with higher rates in the 60-mg dose group.

  • 5

    The study's findings may not directly apply to Western populations due to differences in body mass index and diabetes characteristics.

Original Source(s)

Oral HRS-7535 Lowered A1c in Trial

  • by Kathryn Wighton

  • June 5, 2026

Related Content

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.

Can Lower Music Levels Preserve Workout Intensity?

Despite preserved exertion perceptions, researchers report limited hearing protection use in group fitness classes.

Mass Spec Roundup: Hidden Origins and Cellular States

New studies separate host and microbial metabolites, trace secreted proteins, identify a pro-regenerative cardiomyocyte state, and map macrophage lipid metabolism

  • June 30, 2026

  • 6 min